Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Maze Therapeutics
company
About
Maze Therapeutics is an operator of a biotechnology firm used to focus on translating genetic insights into new medicines.
- 101 - 250
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $190M
- Industries
- Biotechnology,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Maze Therapeutics is a biotechnology firm used to focus on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics, and an array of drug discovery approaches. and it also reveals modifier genes that confer protection and provide a deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$381M
Maze Therapeutics has raised a total of
$381M
in funding over 2 rounds. Their latest funding was raised on
Jan 10, 2022 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 10, 2022 | Series Unknown | $190M | 1 | — | — | Detail |
| Feb 28, 2019 | Series A | $191M | 1 |
ARCH Venture Partners
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Maze Therapeutics is funded by 2 investors.
ARCH Venture Partners
and General Catalyst
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
Yes | Series A |
General Catalyst
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
